



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
octreotide

Effective Date: Dec 2011	CLASSIFICATION Hormone Antidote	OTHER NAMES Sandostatin	PAGE 1 of 2
Revised Date: June 2024			

ADMINISTRATION POLICY:
 IV Infusion – May be administered by a nurse
 Subcutaneous – May be administered by a nurse
 IV Injection – May be administered by a nurse
 IM Injection – *Not to be administered*

RECONSTITUTION/DILUTION/ADMINISTRATION:
Available as: 200 mcg/mL – 5 mL multidose vials REFRIGERATE. **DO NOT FREEZE.**
 100 mcg/mL, 500 mcg/mL single use vials

Subcutaneous: Administer dose undiluted

IV bolus: Administer undiluted over 1 to 2 minutes

IV intermittent: Administer over 15 to 30 minutes

Dose	Dose Preferred Diluent Volumes Bag size NaCl 0.9% or D5W
Ordered	50mL or 100mL

IV Infusion: Pump Library: *Note: 0.5 mg = 500 mcg*

Drug Library	Dose Rate	Short Name	Care Unit
Yes	mcg/h	octreot	General & Critical Care
Drug	Diluent	Final Volume (VTBI)	Final Concentration
500 mcg (1 mL of 0.5 mg/mL)	100 mL NS	101 mL (rounded)	5 mcg/mL
Clinical Advisory:			
Soft Low Dose Limit: 25 mcg/h		Soft High Dose Limit: 50 mcg/h	

Drug Library	Dose Rate	Short Name	Care Unit
Yes	mcg/h	octreot.	General & Critical Care
Drug	Diluent	Final Volume (VTBI)	Final Concentration
500 mcg (x mL of x mg/mL)	100mL	variable	variable
Clinical Advisory:			
Soft Low Dose Limit: 25 mcg/h		Soft High Dose Limit: 50 mcg/h	



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
octreotide

Effective Date: Dec 2011 Revised Date: June 2024	CLASSIFICATION Hormone Antidote	OTHER NAMES Sandostatin	PAGE 2 of 2
---	--	--	-----------------------

DOSAGE:
Subcutaneous is the preferred route for most indications. See Additional Notes.

Bleeding gastroesophageal varices: IV bolus: 25 to 100 mcg followed by
IV continuous: 25 to 50 mcg/hour for 2 to 5 days

Other indications: IV intermittent/subcutaneous: 100 to 600 mcg daily in 2 to 4 divided doses

Hypoglycemia due to sulfonylurea overdose (in combination with IV dextrose):
Subcutaneous: 50 to 100 mcg every 8 or 12 hours OR
IV continuous: 50 mcg/hour

Maximum single dose: 500 mcg
Maximum daily dose: 1500 mcg
Maximum rate: IV bolus: 100 mcg over 1 minute
IV continuous: 50 mcg/hour
Maximum concentration: IV bolus: undiluted

STABILITY/COMPATIBILITY:

Stability of vial: May be stored at room temperature for a maximum of 14 days once removed from refrigerator

Stability of Final Admixture: 24 hours at room temperature

Compatibility: Compatible with normal saline, D5W

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Nausea, abdominal discomfort, diarrhea, vomiting, hypothyroidism, hyperglycemia or hypoglycemia

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Pain at injection site – may diminish within 15 minutes and may be minimized by warming solution to room temperature before administration
- Subcutaneous Administration: Remove drug from fridge for 20 minutes prior to subcutaneous administration to minimize local reaction. In addition, it is recommended that site rotation be used. It is the usual route for control of symptoms associated with carcinoid or gastro-intestinal tumors due to delayed absorption and prolonged activity.
- The IV route is generally reserved for emergency situations